Citation Impact
Citing Papers
Rhizobium induces DNA damage in Caenorhabditis elegans intestinal cells
2019 StandoutNobel
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Breast cancer
2019 Standout
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis.
2010
A polymorphism in the CYP17 gene is associated with male breast cancer
1999
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
2013
The relationship between prognostic and predictive factors in the management of breast cancer
1998
A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
2010
Triple-Negative Breast Cancer
2010 Standout
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
2012
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
Cardiac side-effects of cancer chemotherapy
2010
Patients' help-seeking experiences and delay in cancer presentation: a qualitative synthesis
2005
Breast cancer
2016 Standout
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
2007 Standout
Role of Transforming Growth Factor β in Human Disease
2000 Standout
How Tumors Become Angiogenic
1996
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
1996 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Growth factors and oncogenes in breast cancer
1990
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY
2006
Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management
2014
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
2010
Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1).
1992
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
MINIREVIEW: Estrogen Receptor Variants in Clinical Breast Cancer
1991
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
2010
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
2002
Accelerated partial irradiation for breast cancer: Systematic review and meta-analysis of 8653 women in eight randomized trials
2014
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
2011
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
2014
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012
Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence
2014
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
2012
Increased frequency of long androgen receptor CAG repeats in male breast cancers
2004
Androgen Receptor Gene Alterations in Finnish Male Breast Cancer
2003
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Male breast cancer
2006 Standout
Transforming growth factor-α messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization
1990
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
2005
Benefits, risks, and safety of external beam radiation therapy for breast cancer
2015
Genetic alterations in breast cancer
1995
Transforming growth factor β1 (TGF-β1) is a preoperative prognostic indicator in advanced gastric carcinoma
1998
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
1995
Mitotic DNA Damage Response: At the Crossroads of Structural and Numerical Cancer Chromosome Instabilities
2017
Ferric Carboxymaltose
2009
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Transforming Growth Factor β in Tissue Fibrosis
1994 Standout
Cardiovascular effects of systemic cancer treatment
2010
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
2011
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
1994
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
2009
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
2000 Standout
TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
1993 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Epoetin alfa improves quality of life in patients with cancer
2004
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer
2013
Orthogonal photoswitching in a multifunctional molecular system
2016 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Emerging targeted agents in metastatic breast cancer
2013
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
2010
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
2011
Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1.
1992
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
1993 StandoutNobel
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Bidirectional Photomodulation of Surface Tension in Langmuir Films
2016 StandoutNobel
Wavelength-selective cleavage of photoprotecting groups: strategies and applications in dynamic systems
2015 StandoutNobel
Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma
1997
Breast Cancer Treatment
2019 Standout
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
2016
Direct and Versatile Synthesis of Red‐Shifted Azobenzenes
2016 StandoutNobel
Boost IORT in Breast Cancer: Body of Evidence
2014
Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis
1999 StandoutScience
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron
2013
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
2013
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Iron-Deficiency Anemia
2015 Standout
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
2010
Emerging Targets in Photopharmacology
2016 StandoutNobel
Elevated serum levels of transforming growth factor-?1 in patients with colorectal carcinoma
1999
Multiple Myeloma
2011 Standout
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
2009
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Cardiac toxicity in cancer survivors
2013
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Unraveling the Photoswitching Mechanism in Donor–Acceptor Stenhouse Adducts
2016 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
2003
ß-Arrestin 2 Mediates Endocytosis of Type III TGF-ß Receptor and Down-Regulation of Its Signaling
2003 StandoutScienceNobel
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Transforming growth factor β and cancer
1995
Works of Peter Barrett‐Lee being referenced
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
2005
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
2000
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial
2015
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
2013
Cardiotoxicity and anthracyclines
2008
The prognostic significance of transforming growth factors in human breast cancer
1993
Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey
2006
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
1992
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
2009
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration
2005
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer
2011
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
2013
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
2014
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
2004
Experiences of men with breast cancer: an exploratory focus group study
2003
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
2013
Transcripts for transforming growth factors in human breast cancer: clinical correlates
1990
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
2009
Growth factor expression in normal, benign, and malignant breast tissue
1988
Male cancer: a qualitative study of male breast cancer
2000
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
2011
Iron and the anaemia of chronic disease: a review and strategic recommendations
2006
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
2007
Characterization of estrogen receptor messenger RNA in human breast cancer.
1987
Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.
2010
Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)
2010